ESR1 and breast cancer: STAT3 activation has been associated with ALDH expression and MFE in triple negative BC cell lines [23, 27] and recently it has been shown that a STAT3 inhibitor blocking phosphorylation can target breast CSCs in ER+ palbociclib-resistant cell lines [28].